cvs caremark - Search News

Modern Healthcare · 2d

Big 3 PBMs reaped $7.3B from generic specialty drug markups: FTC

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.

Business Insider · 2d

FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on

PBMs made more than $7B marking up specialty generics: FTC

The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty generic drugs for cancer and other conditions.

Becker's Hospital Review · 1d

FTC finds top 3 PBMs inflated drug prices by $7.3B

The three PBMs inflated the drug prices dispensed at their affiliated pharmacies by hundreds and thousands of percent passing costs onto patients, employers and healthcare plans, according to a Jan. 14 news release from the agency.

Seeking Alpha on MSN · 1d

FTC finds PBMs excessively marked up prices on specialty drugs

A new report issued by the Federal Trade Commission has found that prescription benefit manager units owned by CVS Health (NYSE:CVS), Cigna (CI) and UnitedHealth Group (UNH) significantly marked up prices for many specialty generic drugs over a six-year period.

21hon MSN

UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

23h

FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

Hosted on MSN1h

UnitedHealth Is Price Gouging Cancer Patients by Overcharging 'Thousands of Percent' for Live-Saving Meds, Pocketing Extra Billions: Feds

The UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases ...

Healthcare Dive7d

CVS successfully converts commercial pharmacy contracts to “cost plus” model

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

1hon MSN

Several Setbacks Dragged CVS Health Corp. (CVS) in Q4

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...

FTC says Minnesota-based Optum, et al., inflate cancer drug prices 1,000%

Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than ...

9d

Zydus announces agreement with CVS Caremark

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...

1d

CVS Health: Current Price Offers Favorable Risk-Reward Profile

The Health Care Benefits segment includes Aetna and other health insurance businesses. CVS acquired Aetna in 2017. In 2023, ...

Hosted on MSN2d

What You Need To Know Ahead of CVS Health's Earnings Release

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...

1d

Bernstein Sticks to Their Hold Rating for CVS Health (CVS)

Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results